{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:05:05Z","timestamp":1773021905411,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Global Infectious Diseases Research and Training Program"},{"name":"Funda\u00e7\u00e3o de Apoio \u00e0 Universidade Federal de S\u00e3o Paulo"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.vaccine.2016.06.072","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T04:03:07Z","timestamp":1467950587000},"page":"4327-4334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Alessandra R.","family":"Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia M.","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aur\u00e9lio P.","family":"S\u00e1fadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta H.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymundo S.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xilian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Y.","family":"Weckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.072_b0005","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Hemoglobinopatias. Doen\u00e7a falciforme. Available at: <http:\/\/www.portal.saude.gov.br\/portal\/saude\/profissional\/default.cfm> [Accessed on 20 Jan 2014]."},{"key":"10.1016\/j.vaccine.2016.06.072_b0010","series-title":"Sickle cell disease","first-page":"153","author":"Serjeant","year":"2001"},{"key":"10.1016\/j.vaccine.2016.06.072_b0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.072_b0020","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.pcl.2013.09.006","article-title":"Sickle cell disease in childhood: from newborn screening through transition to adult medical care","volume":"60","author":"Quinn","year":"2013","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.072_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0163-4453(83)90863-0","article-title":"Sickle cell disease and infection","volume":"7","author":"Onwubalili","year":"1983","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.06.072_b0030","series-title":"Hematology of infancy and childhood","first-page":"762","article-title":"Sickle cell disease","author":"Dover","year":"1998"},{"key":"10.1016\/j.vaccine.2016.06.072_b0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jcp.54.3.214","article-title":"Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed","volume":"54","author":"Waghorn","year":"2001","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0040","first-page":"1","article-title":"Prevention and control of meningococcal disease \u2014 recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.06.072_b0045","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade. Casos confirmados de meningite no Sistema de Informa\u00e7\u00f5es de Agravos de Notifica\u00e7\u00e3o em 2014. Available at: <http:\/\/dtr2004.saude.gov.br\/sinanweb\/tabnet\/tabnet?sinannet\/meningite\/bases\/> [Accessed on 22 May 2015]."},{"key":"10.1016\/j.vaccine.2016.06.072_b0050","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Programa Nacional de Imuniza\u00e7\u00f5es. Manual dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. 3. ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2006. 188 p."},{"key":"10.1016\/j.vaccine.2016.06.072_b0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.06.072_b0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0070","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"364","key":"10.1016\/j.vaccine.2016.06.072_b0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"24\u201330","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.072_b0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.072_b0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4161\/hv.4.4.5437","article-title":"Sustaining immunity after immunization against encapsulated bacteria","volume":"4","author":"Blanchard-Rohner","year":"2008","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2016.06.072_b0090","series-title":"Vaccines","first-page":"14","article-title":"Vaccine immunology","author":"Siegrest","year":"2013"},{"key":"10.1016\/j.vaccine.2016.06.072_b0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0100","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/jcm.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.06.072_b0105","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0110","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus: I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.072_b0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus: II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.072_b0120","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization","volume":"43","author":"Snape","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0125","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.06.072_b0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-2478(92)90215-A","article-title":"Low number of antibody producing cells in patients with sickle cell anemia","volume":"34","author":"Rautonen","year":"1992","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2016.06.072_b0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ajcp\/84.2.153","article-title":"B-cell changes occur in patients with sickle cell anemia","volume":"84","author":"Venkataraman","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0140","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.06.072_b0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(10)61493-6","article-title":"Post-splenectomy and hyposplenic states","volume":"378","author":"Di Sabatino","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.072_b0150","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroups C conjugate vaccine in asplenic individuals","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.072_b0155","unstructured":"Paronetto CCL, Gorla MC, Brand\u00e3o A, Appenzeller S, Weckx LY. Evaluation of immune response of meningococcal serogroup C conjugate vaccine in sickle cell disease and splenectomized patients. In: 49th interscience conference on antimicrobial agents and chemoterapy, S\u00e3o Francisco; 2009."},{"key":"10.1016\/j.vaccine.2016.06.072_b0160","first-page":"262","article-title":"Pattern of splenic phagocytic function in Brazilian patients with sickle cell disease","volume":"110","author":"Groto","year":"1992","journal-title":"Rev Paul Med"},{"key":"10.1016\/j.vaccine.2016.06.072_b0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0031-3955(05)70426-0","article-title":"Sickle cell disease","volume":"43","author":"Lane","year":"1996","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.vaccine.2016.06.072_b0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1542\/peds.76.3.392","article-title":"Developmental pattern of splenic dysfunction in sickle cell disorders","volume":"76","author":"Pearson","year":"1985","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.06.072_b0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pbc.22461","article-title":"Susceptibility to invasive bacterial infections in children with sickle cell disease","volume":"55","author":"Battersby","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2016.06.072_b0180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2013.09.001","article-title":"Management of sickle cell disease from childhood through adulthood","volume":"27","author":"Kanter","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.vaccine.2016.06.072_b0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/pr.2013.227","article-title":"Emerging science of hydroxyurea therapy for pediatric sickle cell disease","volume":"75","author":"Green","year":"2014","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2016.06.072_b0190","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.12323","article-title":"The effect of hydroxcarbamide therapy on survival of children with sickle cell disease","volume":"161","author":"Lobo","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0195","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.06.072_b0200","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Efectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.072_b0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.06.072_b0215","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-202561","article-title":"Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study","volume":"73","author":"Stoof","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2016.06.072_b0220","article-title":"Use of men ACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013 (ACIP), 2014","volume":"63","author":"Centers for Disease Control and Prevention (CDC)","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.06.072_b0225","series-title":"Immunisation against infectious disease. (Green Book)","article-title":"Immunisation of individuals with underlying medical conditions","author":"Salisbury","year":"2014"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.072_b0230","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0235","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Programa Nacional de Imuniza\u00e7\u00f5es. Manual dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. 4. ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2014. 160 p."},{"key":"10.1016\/j.vaccine.2016.06.072_b0240","unstructured":"Pan American Health Organization. Informe Regional de SIREVA II: Datos por pa\u00eds y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Streptococcus pneumoniae, Haemophilus influenza y Neisseria meningitidis, en procesos invasores, 2013. OPS. OMS. Unidad de Inmunizaci\u00f3n Integral de la Familia, Departamento de Familia, G\u00e9nero y Curso de Vida (FGL\/IM). Washington, DC: Pan American Health Organization; 2015."},{"key":"10.1016\/j.vaccine.2016.06.072_b0245","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Introdu\u00e7\u00e3o da vacina meningoc\u00f3cica C (conjugada) no calend\u00e1rio de vacina\u00e7\u00e3o da crian\u00e7a. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica \u2013 Bras\u00edlia (DF); 2010: 1\u201318."},{"key":"10.1016\/j.vaccine.2016.06.072_b0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jpids\/piu027","article-title":"Meningococcal disease: epidemiology and early effects of immunization programs","volume":"3","author":"S\u00e1fadi","year":"2014","journal-title":"J Ped Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0255","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.072_b0260","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/INF.0000000000000853","article-title":"Prevalence, risk factors and molecular characteristics of meningococcal carriage among Brazilian adolescents","volume":"34","author":"de Moraes","year":"2015","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:05:32Z","timestamp":1668639932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":52,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0264410X16305497"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}